Published in final edited form as:

Chem Commun (Camb). 2008 October 21; (39): 4768–4770. doi:10.1039/b809099h.

Auto-hydroxylation of FIH-1: an Fe(II), α -ketoglutarate-dependent human hypoxia sensor†

Yuan-Han Chen^{a,b}, Lindsay M. Comeaux^b, Stephen J. Eyles^c, and Michael J. Knapp^{a,b}

^a Department of Chemistry, University of Massachusetts, Amherst, Massachusetts 01003, USA. E-mail: mknapp@chem.umass.edu; Fax: +1 413-545-4490; Tel: +1 413-545-4001

^b Program in Molecular and Cellular Biology, University of Massachusetts, Amherst, Massachusetts 01003, USA

^c Department of Polymer Science and Engineering, University of Massachusetts, Amherst, Massachusetts 01003, USA

Abstract

HIF-asparaginyl hydroxylase (FIH-1) normally couples O₂-activation to hydroxylation of Asn⁸⁰³ on the α -subunit of the hypoxia-inducible factor (HIF α), a key step in *p*O₂ sensing; in the absence of HIF α , O₂-activation becomes uncoupled, leading to self-hydroxylation at Trp²⁹⁶ and a purple Fe(III)–O–Trp chromophore—this alternative reactivity may affect human hypoxia sensing.

Cellular responses to O₂ levels are central to human health, controlling processes such as angiogenesis and basal metabolism.^{1,2} Tight regulation of O₂ is necessary, as while it is required for aerobic metabolism, an excess can lead to oxidative damage. In humans, the master regulator of O₂-homeostasis is a transcription factor called the hypoxia-inducible factor (HIF), which is inactivated by HIF-asparaginyl hydroxylase (previously identified as FIH-1), a non-heme, Fe(II), α -ketoglutarate (α KG)-dependent dioxygenase.^{3–5} While tight coupling between O₂-activation and HIF-hydroxylation would be expected for optimal O₂ sensing, some α KG-dependent dioxygenases exhibit uncoupled O₂-activation. We establish here that FIH-1 self-hydroxylates in the absence of HIF, suggesting that uncoupling between O₂ and HIF may alter the activity levels of FIH-1.

HIF is a heterodimeric transcription factor, consisting of the HIF α monomer, which is regulated in response to *p*O₂, and the ARNT monomer, which is insensitive with respect to *p*O₂. Under the conditions of hypoxia (low *p*O₂), HIF assembles the transcriptional co-activator, p300, upstream from HIF controlled genes, thereby promoting the expression of over 100 genes involved in iron transport, angiogenesis and basal metabolism.^{1,6} The key intermolecular interactions are found between transcriptional machinery and the C-terminal domain of HIF α .^{7,8} FIH-1 uses O₂ to hydroxylate the β -carbon of HIF α -Asn⁸⁰³,⁹ preventing p300 from binding to HIF α , and thereby turning off gene expression in response to increasing *p*O₂.

Although the sensing of *p*O₂ should require tight coupling between *p*O₂ and the hydroxylation of HIF α , the chemical mechanism of FIH-1 activity suggests that O₂ consumption could be uncoupled from HIF-hydroxylation. In the consensus mechanism, HIF α binding displaces the axial H₂O from the Fe(II)– α KG center, which opens up a coordination site for O₂ binding.^{10,11} This leads to the formation of the Fe(IV) = O intermediate, but only when the HIF α -

†Electronic supplementary information (ESI) available: ESI-MS/MS spectra of trypsin-digested purple FIH-1.

Correspondence to: Michael J. Knapp.

Asn⁸⁰³ sidechain is nearby, ensuring that O₂-activation only occurs when HIF α is present. However, spectroscopic studies suggest that the axial H₂O in other members of the Fe(II), α KG-dependent dioxygenases can be released, even in the absence of a prime substrate,^{12, 13} if this occurred on FIH-1, it would lead to uncoupling between O₂ and HIF α . It is notable that in activity assays of FIH-1 and many other members of the non-heme, Fe(II), α KG-dependent dioxygenase superfamily, excess ascorbate was required for full activity, as this maintained the iron in the reduced state.¹⁰

In addition, a few members of this superfamily deactivate by auto-hydroxylation in the absence of a prime substrate. For example, aromatic residues within the active site of TauD (Tyr)¹⁴ and TfdA (Trp)¹⁵ are hydroxylated during uncoupling to generate an Fe(III) coordinated by an aromatic alcohol, suggesting that the electrophilic Fe(IV) = O species can oxidatively attack residues within ~10 Å of it, to create new metal-binding ligands. The active site of FIH-1 contains three aromatic residues that, based upon these chemical precedents in bacterial enzymes, could be susceptible to hydroxylation.

To determine whether FIH-1 can auto-hydroxylate, apo- FIH (100 μ M in 50 mM HEPES, pH 7.50), FeSO₄ (500 μ M) and α KG (500 μ M) were incubated anaerobically in a sealed cuvette for 1 h. The absorption spectrum was measured, and it showed a moderate-intensity absorption near 520 nm, which could be attributed to the Fe(II)– α KG charge transfer that would be expected for resting FIH-1.¹⁷ The cuvette was then opened to air to introduce O₂, with the reaction being monitored by a UV-vis spectrophotometer over 10 000 seconds. A new absorption band appeared at $\lambda_{\text{max}} = 583$ nm ($\epsilon_{583} = 3 \times 10^3 \text{ M}^{-1} \text{ cm}^{-1}$), which was consistent with the product of auto-hydroxylation: Fe(III) coordinated to an aromatic alcohol (Fig. 1). Negative controls, in which any individual component was omitted, showed that this chromophore required FIH-1, Fe(II), O₂ and α KG for its formation.

Auto-hydroxylation in TauD leads to the formation of a hydroxylated Tyr residue, resulting in an Fe(III)-catecholate with $\lambda_{\text{max}} = 550$ nm ($\epsilon = 700 \text{ M}^{-1} \text{ cm}^{-1}$).¹⁴ A better spectroscopic match to the FIH-1 product is the Fe(III)-(hydroxy-Trp) formed by the auto-hydroxylation of TfdA, with $\lambda_{\text{max}} = 580$ nm ($\epsilon = 1000 \text{ M}^{-1} \text{ cm}^{-1}$),¹⁵ suggesting that the purple chromophore that was formed by the auto-hydroxylation of FIH-1 contained a hydroxylated Trp residue, HO-Trp. Inspection of the FIH-1 sequence indicated that the Trp and Tyr residues within the active site (Fig. 2) would be located on separate tryptic fragments, suggesting that MS could be used to identify the hydroxylation site.

MS was used to identify the site of hydroxylation in a tryptic digest of FIH-1. The tryptic digest was separated by reverse-phase HPLC and detected *via* ESI-MS analysis performed on an ESI-Q-TOF instrument.[‡] LC-MS/MS analysis of the tryptic digest showed that the tryptic fragments containing Tyr⁹³ and Tyr¹⁰² were unmodified, while the fragment containing Trp²⁹⁶ (252–298, 5512.7 Da) appeared at $m/z = 1379.2$ (unmodified, MH₄⁴⁺) and 1383.2 (+16 Da, OMH₄⁴⁺) as $z = 4+$ ions. Co-elution of modified and unmodified Trp²⁹⁶ fragments revealed relative intensities of MH₄⁴⁺: (OMH₄⁴⁺) ~ 7:3 (Fig. 3).[‡]

The hydroxylated residue was identified by LC purification of the Trp²⁹⁶ peptides, followed by direct infusion into the ESI-TOF spectrometer. ESI-MS/MS analysis was performed on the

[‡]Experimental details: FIH-1 (10 μ M) was digested by trypsin overnight (37 °C, 50 mM Tris, pH 8.00, 1 mM CaCl₂). The tryptic digest (30 μ l injection) was separated by reverse-phase HPLC, using a CH₃CN/H₂O (0.1% formic acid) gradient, over a 150 $\times$ 2.1 mm PLRP-S column with a 300 Å pore size and a 3 μ m particle size (Polymer Laboratories, Amherst, MA). High resolution MS utilized a Qstar XL hybrid ESI-TOF spectrometer (Applied Biosystems, Inc.) that was set to detect positive ions over the 500–2000 m/z range, and fragment the 3+, 4+ and 5+ ions of the unmodified peptide (1838.6, 1379.2 and 1103.5 m/z) and hydroxylated peptide (1843.9, 1383.2 and 1106.7 m/z). The positive ions of the 252–298 peptide fragment were found at both unmodified (5512.7 Da) and O-atom added (5528.7 Da) masses.

$z = 4+$ ions for both peptide peaks. The b- and y-ion sequence of the MH_4^{4+} ion corresponded to the genetically encoded sequence. In contrast, the b- and y-ion sequence of the OMH_4^{4+} ion revealed that the additional O-atom was located on Trp^{296} (Table 1). This positively identified the active-site Trp residue as the sole site of O-atom insertion.

The purple chromophore that formed on FIH-1 was identified as an $\text{Fe(III)-O-Trp}^{296}$ species by the identification of O-atom addition to Trp^{296} and its similarity to the blue Fe(III)-O-Trp chromophore found in TfdA. While the Trp^{296} of FIH-1 is separated in a 1° sequence from the Fe ligands, it is positioned very close ($<5 \text{ \AA}$) to the Fe center. As C7 of the indole ring of Trp^{296} is located closest to the Fe, this may be the site of hydroxylation.

By analogy to the consensus chemical mechanism for normal turnover,¹⁰ we propose that the Fe(III)-O-Trp center in FIH-1 is formed by the uncoupled activation of O_2 , leading to the formation of an Fe(IV)=O intermediate in the absence of HIF α . H-atom abstraction, followed by rebound, led to HO-Trp^{296} and Fe(II) , which, through subsequent oxidation and coordination, formed the observed Fe(III)-O-Trp species. As the normal rate of turnover for FIH-1 to hydroxylate HIF α substrates is *ca.* 0.24 s^{-1} ,^{18,19} and the auto-hydroxylation occurred on the timescale of hours, auto-hydroxylation would only be kinetically relevant under conditions of low HIF α concentration.

We speculate that the auto-hydroxylation of FIH-1 may comprise an important regulatory feature of physiological hypoxia sensing. Under normoxic conditions, HIF α is rapidly degraded within cells, thereby depleting FIH-1 of its physiological substrate—such conditions would favor uncoupled O_2 -activation. As suggested within the context of TauD and TfdA function,¹⁰ FIH-1 auto-hydroxylation may protect the cell from deleterious effects of reactive oxygen species by serving in a sacrificial role. Alternatively, auto-hydroxylation may serve as a negative feedback mechanism to regulate hypoxia sensing by reducing the activity of FIH-1.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Acknowledgement is made to the University of Massachusetts, the American Cancer Society (#IRG 93-033) and the NIH (GM077413) for funding.

Notes and references

1. Schofield CJ, Ratcliffe PJ. *Nat Rev Mol Cell Biol* 2004;5:343–354. [PubMed: 15122348]
2. Guillemin K, Krasnow MA. *Cell* 1997;89:9–12. [PubMed: 9094708]
3. Mahon PC, Hirota K, Semenza GL. *Genes Dev* 2001;15:2675–2686. [PubMed: 11641274]
4. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ. *J Biol Chem* 2002;277:26351–26355. [PubMed: 12042299]
5. Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK. *Genes Dev* 2002;16:1466–1471. [PubMed: 12080085]
6. Semenza GL. *Science* 2007;318:62–64. [PubMed: 17916722]
7. Dames SA, Martinez-Yamout M, De Guzman RN, Dyson HJ, Wright PE. *Proc Natl Acad Sci U S A* 2002;99:5271–5276. [PubMed: 11959977]
8. Freedman SJ, Sun ZYJ, Poy F, Kung AL, Livingston DM, Wagner G, Eck MJ. *Proc Natl Acad Sci U S A* 2002;99:5367–5372. [PubMed: 11959990]
9. McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ. *Biochem J* 2002;367:571–575.

10. Hausinger RP. Crit Rev Biochem Mol Biol 2004;39:21–68. [PubMed: 15121720]
11. Zhou J, Gunsior M, Bachmann BO, Townsend CA, Solomon EI. J Am Chem Soc 1998;120:13539–13540.
12. Zhou J, Kelly WL, Bachmann BO, Gunsior M, Townsend CA, Solomon EI. J Am Chem Soc 2001;123:7388–7398. [PubMed: 11472170]
13. Neidig ML, Brown CD, Light KM, Fujimori DG, Nolan EM, Price JC, Barr EW, Bollinger JM, Krebs C, Walsh CT, Solomon EI. J Am Chem Soc 2007;129:14224–14231. [PubMed: 17967013]
14. Ryle MJ, Liu A, Muthukumaran RB, Ho RYN, Koehntop KD, McCracken J, Que L, Hausinger RP. Biochemistry 2003;42:1854–1862. [PubMed: 12590572]
15. Liu A, Ho RYN, Que LJ, Ryle MJ, Phennney BS, Hausinger RP. J Am Chem Soc 2001;123:5126–5127. [PubMed: 11457355]
16. Elkins JM, Hewitson KS, McNeill LA, Seibel JF, Schlemminger I, Pugh CW, Ratcliffe PJ, Schofield CJ. J Biol Chem 2003;278:1802–1806. [PubMed: 12446723]
17. Solomon EI, Brunold TC, Davis MI, Kemsley JN, Lee SK, Lehnert N, Neese F, Skulan AJ, Yang YS, Zhou J. Chem Rev 2000;100:235–349. [PubMed: 11749238]
18. Hewitson KS, McNeill LA, Riordan MV, Tian YM, Bullock AN, Welford RW, Elkins JM, Oldham NJ, Bhattacharya S, Gleadle JM, Ratcliffe PJ, Pugh CW, Schofield CJ. J Biol Chem 2002;277:26351–26355. [PubMed: 12042299]
19. Ehrismann D, Flashman E, Genn DN, Mathioudakis N, Hewitson KS, Ratcliffe PJ, Schofield CJ. Biochem J 2007;401:227–234. [PubMed: 16952279]

Fig. 1. The UV-vis absorption spectrum of FIH-1 (100 μ M in 50mM HEPES, pH 7.50), FeSO_4 (500 μ M) and α KG (500 μ M). (A) Anaerobic conditions, (B) following exposure to air.

Fig. 2.
Aromatic residues within the active site of FIH-1 (PDB 1H2K).¹⁶

Fig. 3.
ESI-TOF spectrum of the tryptic digest fragment 252–298 from purple FIH-1.

Table 1

Observed y-ions from ESI-MS/MS analysis of the Trp²⁹⁶ peptide (252–298) by direct infusion and fragmentation of the $z=4+$ ion at $m/z = 1383.2$

Amino acid	y-ion number	Unmodified m/z observed (calc.)	Modified m/z observed (calc.)
T	7		973.48 (973.48)
V	6		872.41 (872.44)
N	5		773.39 (773.37)
F	4		659.35 (659.32)
W	3		512.28 (512.26)
Y	2	310.19 (310.18)	
K	1	147.11 (147.11)	